82 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
%); no grade 5 TRAEs or febrile neutropenia were reported. The majority of Grade 4 neutropenia events occurred in the first cycle of treatment
8-K
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
%) and decreased white blood cell count (15%); no grade 5 TRAEs or febrile neutropenia were reported.
The majority of Grade 4 neutropenia events occurred
S-8
EX-99.3
fuphemqg
16 Jan 24
Registration of securities for employees
4:03pm
S-8
EX-99.4
ktfg2z lxais039va
16 Jan 24
Registration of securities for employees
4:03pm
S-3ASR
r67w jdxeobw0jc
8 Dec 23
Automatic shelf registration
9:16am
8-K
4bf utuqyu
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
7a246b
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-10.1
8w7ps
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
8-K
EX-4.1
h7isb32235scns 4nqa
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
8-K
EX-10.2
e4cnrhj 3nms0ttg6
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
EX-4.5
rlq3wr
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
uyhwaupx bfqailk
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.4
edynqh
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.6
h8mcpgq
7 Nov 23
Automatic shelf registration
5:24pm
S-3ASR
EX-4.7
acbwecnxq5ilmh
7 Nov 23
Automatic shelf registration
5:24pm